Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a woman aged 18 to 70 years old who has not yet received treatment for breast cancer
- You have a good general level of health and are able to carry out daily activities with little or no limitation (confirm with trial site)
- You have been diagnosed with HER2-positive (hormone receptor negative) or triple-negative invasive breast cancer at an early stage, where the cancer has not spread to the lymph nodes
- Your heart is pumping blood well, with a heart function score of 50% or above
- Your heart's electrical activity (measured by an ECG) is within an acceptable range
- Your blood and organ function (including liver and kidneys) meet specific healthy levels as measured by blood tests (confirm with trial site)
- If you have not gone through menopause or had surgery to prevent pregnancy, you must agree to use effective birth control during the study and for at least 2 months after your last dose
- You are willing to sign a consent form, follow the study rules, and attend follow-up appointments
Who may not be able to join:
- You have a type of breast cancer called inflammatory breast cancer
- Your cancer has spread to other parts of the body (metastatic cancer)
- You have had or currently have another type of cancer that could affect your safety in this study
- You currently have an active infection that requires treatment with medicine
- You have taken any of the study medications within the 14 days before joining
- You have had major surgery (not including a biopsy) within the 14 days before joining
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: XUCHEN CAO, MD, TianJin Medical University Cancer Institute and Hospitall
Phone: 8613512891631
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
5-year EFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.